Abstract: INFO19-SA
Aurora: A Multi-Site Clinical Implementation Network for IgA Nephropathy
Session Information
- Informational Posters - 3
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- No subcategory defined
Authors
- Tangri, Navdeep, University of Manitoba, Winnipeg, Manitoba, Canada
- Nigwekar, Sagar U., Harvard Medical School, Boston, Massachusetts, United States
- Udani, Suneel M., Nephrology Associates of Northern Illinois, Chicago, Illinois, United States
- Weins, Astrid, Mass General Brigham Inc, Boston, Massachusetts, United States
- Sharma, Amit, Vera Therapeutics Inc, Brisbane, California, United States
- Jackson, Jay, Vera Therapeutics Inc, Brisbane, California, United States
Description
Substantial variation exists with risk assessment, monitoring, and treatment of patients with IgA nephropathy (IgAN). Differences in clinical workflows, care coordination, and implementation of evidence-based practices contribute to variability in patient management and may lead to sub-optimal care across academic and community settings. Scalable clinical implementation models that harmonize care across diverse practice environments remain limited.
Aurora is a clinician-led, multi-site clinical implementation learning network designed to improve consistency of IgAN care. Built on a hub-and-spoke model, Aurora integrates multidisciplinary collaboration, standardized care pathways, quality measurement, and continuous feedback to enhance patient care while preserving local clinical autonomy.
The program utilizes a prospective three-phase framework: (1) baseline assessment of gaps in care delivery; (2) implementation of clinical education, integrated workflow decision support, audit and feedback, peer benchmarking, and monitoring pathways; and (3) longitudinal evaluation of real-world outcomes of care delivery and trends in kidney function. Participating sites identify patients with IgAN through electronic health record–based queries and apply standardized approaches to risk assessment, monitoring, and treatment optimization. Implementation activities are embedded within routine clinical workflow and supported through ongoing collaboration across participating sites. Key implementation measures include kidney function monitoring (including eGFR and proteinuria), serial risk assessment for kidney disease progression and cardiovascular morbidity, adoption of IgAN therapies, and adherence to care processes.
Aurora establishes a scalable clinical implementation model to improve consistency of IgAN care across diverse clinical nephrology settings. By combining structured assessment, targeted implementation interventions, continuous performance measurement, and collaborative learning, Aurora offers a reproducible framework for translating evidence into routine clinical practice.
Funding
- Vera Therapeutics